Back to today’s briefing

Story perspectives

Duravyu Misses Primary Endpoint in Lugano Wet AMD Trial

8/18/2026

30 6 Full Breakdown

Summary

Story summary

EyePoint said Duravyu missed the primary endpoint in the Lugano wet AMD trial.
Aflibercept improved acuity by >5 letters, while Duravyu improved by 0-5 letters.
Nine of 211 Duravyu patients lost >=15 letters, whereas no aflibercept patient did.
Duravyu cut injection burden by 42% and had a safety profile.
Shares fell >70% to $4.16-$4.28 while EyePoint plans a first-half-2027 filing after Lucia results in October.

1 of 1

Story summary

EyePoint said Duravyu missed the primary endpoint in the Lugano wet AMD trial.
Aflibercept improved acuity by >5 letters, while Duravyu improved by 0-5 letters.
Nine of 211 Duravyu patients lost >=15 letters, whereas no aflibercept patient did.
Duravyu cut injection burden by 42% and had a safety profile.
Shares fell >70% to $4.16-$4.28 while EyePoint plans a first-half-2027 filing after Lucia results in October.